Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | FBP1 | P09467 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3777037 | 1.00 | ALDH1A1 (0.43) | ALDH1A1HTTPTGS1CYP19A1BRAF | |
| SCHEMBL2920260 | 0.86 | PTGS1 (0.50) | ALDH1A1HTTPTGS1CYP19A1BRAF | |
| SCHEMBL3767391 | 0.86 | PTGS1 (0.50) | ALDH1A1HTTPTGS1CYP19A1BRAF | |
| SCHEMBL3767517 | 0.78 | ALDH1A1 (0.41) | ALDH1A1HTTMAOB | |
| SCHEMBL3767511 | 0.78 | ALDH1A1 (0.41) | ALDH1A1HTTMAOB | |
| SCHEMBL22501039 | 0.77 | CYP19A1 (0.48) | PTGS1CYP19A1KDM4EPTGS2MAOB | |
| SCHEMBL22501036 | 0.77 | CYP19A1 (0.48) | PTGS1CYP19A1KDM4EPTGS2MAOB | |
| SCHEMBL2799258 | 0.77 | MEN1 (0.37) | ALDH1A1HTTPTGS1TRPA1FBP1 | |
| SCHEMBL2799262 | 0.77 | MEN1 (0.37) | ALDH1A1HTTPTGS1TRPA1FBP1 | |
| SCHEMBL3124317 | 0.76 | MAOB (0.43) | ALDH1A1HTTPTGS1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317515-A1 | Azolylmethyloxiranes, use Thereof and Agents Containing the Same | BASF SE (DE) | 2010-12-16 | — | — | US | disclosed |
| EP-2234488-A2 | AZOLYLMETHYLOXIRANES, USE THEREOF AND AGENTS CONTAINING THE SAME | BASF SE (DE) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009077443-A2 | AZOLYLMETHYLOXIRANES, USE THEREOF AND AGENTS CONTAINING THE SAME | BASF SE (DE) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317515-A1 | Azolylmethyloxiranes, use Thereof and Agents Containing the Same | XDH, NOX5, TET1 | ALDH1A1 20/4885HTT 3139/4885PTGS1 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.